Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $62.86 --0%
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 44
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 9 | New: 44
Join SI Premium – FREE
Morgan Stanley analyst David Risinger downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight with a price target of $62.00 (from $70.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $62.89 yesterday.
You May Also Be Interested In
- Eli Lilly (LLY) PT Raised to $1,500 at JPMorgan as Guidance Raise Expected
- DA Davidson Downgrades Manhattan Associates (MANH) to Neutral
- Raymond James Assumes Acadia Healthcare (ACHC) at Outperform
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
